Industry
Biotechnology
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Loading...
Open
10.52
Mkt cap
210M
Volume
24K
High
10.60
P/E Ratio
-1.92
52-wk high
12.89
Low
10.40
Div yield
N/A
52-wk low
2.69
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 9:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 9:12 am
Portfolio Pulse from Avi Kapoor
October 14, 2024 | 2:29 pm
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 7:29 am
Portfolio Pulse from Benzinga Insights
October 01, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 1:35 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 8:40 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 11:51 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.